Seroprevalence and correlates of HIV, syphilis, and hepatitis B and C virus among intrapartum patients in Kabul, Afghanistan

Table 4 Hepatitis B acquisition and future burden estimates for infants born in government maternity hospitals with 85% birth dose hepatitis B vaccine coverage vaccination programming in Kabul, Afghanistan.

	Number Without Program	Number With Program	Number Prevented	Percent Reduction
A. Disease Events Prevented (Future burden)
Total HBV infections	27,054	19,708	7,346	27%
Acute symptomatic hepatitis B cases	5,400	3,933	1,467	27%
Chronic HBV infections	4,937	3,600	1,337	27%
HBV-related deaths:
Acute hepatitis B	23	17	6	27%
Cirrhosis	268	195	73	27%
Hepatocellular carcinoma	170	124	46	27%
Total Deaths	460	336	125	27%
B. Number of Infections by Age at Acquisition of Infection (Future burden)
Perinatal Infection	117	90	27	23%
Early Childhood Infection	13,410	9,766	3,643	27%
Late Infection	13,527	9,852	3,675	27%
Total Infections	27,054	19,708	7,346	27%
C. Number of Chronic Infections by Age at Acquisition of Infection (Future burden)
Perinatal Infection	106	81	24	23%
Early Childhood Infection	4,021	2,929	1,093	27%
Late Infection	811	590	220	27%
Total Infections	4,937	3,600	1,337	27%
D. Number of Deaths by Age at Acquisition of Infection (Future burden)
Perinatal Infection	9	7	2	23%
Early Childhood Infection	362	264	98	27%
Late Infection	89	65	24	27%
Total Deaths	460	336	125	27%
E. Number of HBV-Related Deaths in 2000 (Current burden)
Acute hepatitis B	166
Cirrhosis	1,130
Hepatocellular carcinoma	795
Total Deaths	2,090
Appendix. Input values
Prevalance HBsAg among women of child bearing age:				1.3
Prevalence HBeAg among HBsAg-positive women of child bearing age:				12.5
Prevalence of any marker of HBV infection among 5 year olds:				30
Prevalence of any marker of HBV infection among 30+ year olds:				60
Estimated Hepatitis B3 coverage:				28.6
Estimated coverage with birth dose hepatitis B vaccine:				85%

ISSN: 1471-2334